GlassScriptPhysician profile
Alecia Green
NPI 1427755065
$7,219.63
in general payments reported to CMS, 2019-2025
33 companies · $2,865 in 2025
The $2,865 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $701 · 2024: $3,654 · 2025: $2,865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,219.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,297.19 | 2023-2025 | |
| Lundbeck LLC | $674.20 | 2023-2025 | Vyepti, Rexulti |
| Avadel Cns Pharmaceuticals, LLC | $593.21 | 2023-2025 | Lumryz |
| Jazz Pharmaceuticals INC. | $505.18 | 2024-2025 | |
| Biogen, INC. | $477.73 | 2023-2025 | Vumerity, Tysabri, Avonex |
| Amneal Pharmaceuticals LLC | $419.22 | 2023-2025 | Crexont, Lyvispah, Rytary |
| Emd Serono, INC. | $385.61 | 2024 | Mavenclad |
| Argenx US, INC. | $248.82 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Acadia Pharmaceuticals INC | $245.24 | 2024-2025 | Nuplazid |
| Neurelis, INC. | $233.36 | 2023-2025 | Valtoco |
| Neurocrine Biosciences, INC. | $211.02 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $187.14 | 2024-2025 | Ponvory |
| Sk Life Science, INC. | $185.74 | 2023-2024 | |
| Genentech USA, INC. | $161.58 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Pfizer INC. | $153.81 | 2023-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $145.95 | 2025 | |
| Ucb, INC. | $143.12 | 2024-2025 | Briviact, Nayzilam |
| Axsome Therapeutics, INC. | $117.37 | 2025 | Symbravo |
| Banner Life Sciences, LLC | $115.02 | 2023-2024 | |
| Lilly USA, LLC | $107.83 | 2023-2025 | Emgality, Reyvow, Amyvid |
| Teva Pharmaceuticals USA, INC. | $99.93 | 2025 | Ajovy |
| Takeda Pharmaceuticals U.S.A., INC. | $84.54 | 2025 | Hyqvia |
| Novartis Pharmaceuticals Corporation | $84.08 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $77.04 | 2024-2025 | Ultomiris |
| Tg Therapeutics, INC. | $77.00 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $49.42 | 2023 | Horizant |
| Impel Pharmaceuticals LLC | $31.41 | 2025 | Trudhesa |
| Aucta Pharmaceuticals, INC. | $23.16 | 2025 | Motpoly Xr |
| Otsuka America Pharmaceutical, INC. | $21.43 | 2024 | Rexulti |
| Cycle Pharmaceuticals INC | $17.91 | 2025 | Tascenso Odt, Bafiertam |
| Merz Pharmaceuticals, LLC | $15.97 | 2025 | Inbrija |
| Owp Pharmaceuticals, INC. | $15.02 | 2024 | Subvenite |
| Scilex Pharmaceuticals INC. | $14.38 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alecia Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.